Inozyme Pharma, Inc. (INZY) Stock Analysis & Investment Frameworks
Inozyme Pharma, Inc. (INZY) stock analysis on Invetso. Review Inozyme Pharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Inozyme Pharma, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Inozyme Pharma, Inc. Key Financial Metrics
- Market Cap: $258.25M
- Revenue: $N/A
- ROE: -102.90%
- ROIC: -99.36%
- Dividend Yield: N/A
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.